Introduction detailed. 6 Patient selection was based upon a minimum duration of Chronic myelogenous leukemia (CML) is a clonal disorder of IFN-␣ treatment of 12 months and the availability of bone the multipotent stem cells. It is characterized by a reciprocal marrow paraffin blocks from the initial diagnostic workup and chromosomal translocation t(9;22)(q34;q11) of the Philadel-1-3 years later while they were still on IFN-␣ therapy and in phia chromosome (Ph) . 1 Many studies indicate that the natural a chronic phase of the disease. We selected patients treated history of CML involves a progressive accumulation of reticuwith IFN-␣ for a minimum of 12 months in order to detect lin in the bone marrow, although the rate of progression varies significant changes in the grade of marrow fibrosis, assuming widely. The development of high grades of marrow fibrosis this period as sufficient time for IFN-␣ to affect fibrosis and of accelerated or blastic phases in CML are assumed to production by bone marrow fibroblasts. be closely related processes; both correlate with a poor progResponse criteria to IFN-␣ therapy were as previously nosis. [2] [3] [4] In addition, increasing bone marrow fibrosis leading reported. 6 A complete hematological remission (CHR) was to complications of bone marrow failure may adversely affect defined by normalization for at least 4 weeks of the bone marbone marrow transplantation (BMT) or generate difficulties in row (less than 5% blasts) and peripheral blood with WBC Ͻ9 bone marrow aspiration for BMT or smears.
5
× 10 9 /l and no peripheral blasts, promyelocytes or myelocytes, Interferon-alpha (IFN-␣) has become an important treatment in addition to disappearance of all signs and symptoms of the modality in CML.
6-10 It produces hematologic remissions in disease including splenomegaly. This was further classified the majority of patients and cytogenetic remissions in up to according to Ph suppression as: (1) no cytogenetic response, 50% of the patients.
6,7 The influence of IFN-␣ therapy on myePh-positive 100%; (2) minor cytogenetic response (MCR), Ph lofibrosis associated with CML has not been thoroughly inves-35-90%; (3) partial cytogenetic response (PCR), Ph 1-34%; tigated. The single study so far published has demonstrated (4) complete cytogenetic response (CHR), Ph 0%. that in a small unselected patient population the speed of progression of bone marrow fibrosis was significantly increased when the patients were treated with IFN-␣ compared to busul-stained with hematoxylin-eosin for morphologic analysis and hematopoiesis were graded for fibrosis, while areas of empty hematopoiesis (fat, infarctions, etc) were not included in the with Snook's reticulin stain (ammoniacal silver procedure) for argyrophilic fibers. Grading of reticulin fibrosis (scale of 1 to grading score. For comparative purposes, 20 bone marrow biopsy samples 4) was according to the quantity and pattern of distribution of reticulin as described:
12,13 grade 1, either minimal reticulin from normal donors and patients with solid tumors who had normal marrow studies during routine workup, were also or reticulin fibers occupying less than 25% of the areas of hematopoiesis showing no hemorrhage or artefactual stained for reticulin and graded in a similar fashion. All 20 control normal bone marrow biopsies samples showed grade depletion of cells, including fat deposition; grade 2, reticulin fibers seen in 25 to 50% of the areas examined; grade 3, 1 reticulin fibrosis. All cases were graded independently by two investigators (CB-R and MW). Prognostic risk group reticulin fibers seen in 50 to 75% of areas examined; grade 4, greater than 75% of marrow containing reticulin. Figure 1 categorization was as previously described. Table 1 . Their median age was 45 years (range, ined at equidistant representative areas of the whole specimen. Slides were moved systematically, and only areas of 22-67 years), and 14 (34%) were females. In this study, we included patients who had been treated with IFN-␣ for a minimum period of 1 year. Only patients Table 1 Study group and response to IFN-␣ therapy (41 patients) with a CHR were included, 17 patients (41%) had a cytogenetic CR, eight (20%) a cytogenetic PR, and 16 (39%) a
Characteristics
No.
minor cytogenetic response. Due to the selection criteria for favorable response with IFN-␣ therapy, 33 patients (81%)
Median age (years) (range) 45 were in the intermediate or good prognostic groups (Table 1) . Interferon-alpha and marrow fibrosis in chronic myeloid leukemia M Wilhelm et al 68 counts Ͼ450 × 10 9 /l (P, not significant). In this study involving
a smaller number of patients, there was also no correlation between platelet counts at diagnosis, or at follow-up, and the reticulin fibrosis grade of the corresponding marrow specimen. The lack of association in our studies between megakaryocyte content, or thrombocytosis, and degree of 2a). Therefore, in 80% of the patients reticulin fibrosis in bone myelofibrosis may be due to several possibilities including, marrow did not worsen or improved with administration of (1) the techniques used; (2) a possible qualitative rather than IFN-␣.
quantitative stimulating effect of fibroblasts by megakaryocytic The correlation between initial and later fibrosis grade on factors; or (3) increased sensitivity of fibroblasts to PDGF IFN-␣ therapy is shown in Table 2b . Only five patients (12%) stimulation as a result of increased receptor sites or intrinsic with limited fibrosis (ie grade 1 or 2) showed an increase alterations of the fibroblasts as part of the CML disease. 26, 27 towards significant fibrosis (ie grade 3 or 4), mostly as an The mechanisms underlying the stimulation of fibrosis by increase by one grade. No patient with grade 3 or 4 fibrosis megakaryocytes has been the subject of numerous investibefore the start of IFN-␣ therapy showed an ongoing accumugations. Intramedullary release of PDGF by megakaryocytes, lation of fibers. Eight of the 18 patients in this group had a and PDGF stimulation of fibroblasts, thus producing fibrosis, decrease of the fibrosis grade and one patient demonstrated has been one postulated sequence. 21,23,28-31 A possible role of a reduction in bone marrow reticulin from grade 4 to normal the cellular oncogene c-sis has also been proposed (c-sis is levels during IFN-␣ therapy.
translocated from chromosome 22 to chromosome 9 in CML), Table 3 shows the correlation of reticulin fibrosis with the but not proven. 32 The sequence homology between PDGF maximum cytogenetic response in patients on IFN-␣ therapy. and p28 sis, the putative transforming protein of Simian sarThere was no obvious correlation between degree of response coma virus, suggests that sis oncogene encodes for a protein and fibrosis patterns during IFN-␣ therapy. There was also no similar or identical to PDGF. These findings indicate a poscorrelation between platelet counts (less vs more than 450 × sible causal association between aberrant c-sis expression, 10 9 /l) at diagnosis or at follow-up, and reticulin fibrosis grade production of PDGF-like protein, and excessive fibroblastic (1-2 vs 3-4) in the corresponding specimen.
stimulation and fibrosis. The recent discovery, cloning and preclinical and clinical trials with thrombopoietin demonstrating its dramatic effect on megakaryopoiesis [33] [34] [35] suggest that Discussion measurements of production of thrombopoietin-like molecules or receptor sites (C-MPL) in CML, or the differential The development of various degrees of bone marrow fibrosis sensitivity of CML marrow fibroblasts to stimulation by these is a common event in the natural history of CML.
2-4 Several molecules should be investigated. Wetzler et al 36, 37 have also studies have demonstrated increasing fibrosis grade to be a found that marrow fibroblasts in CML may participate actively marker of disease progression, and to be associated with in the perpetuation of CML progression through paracrine loops involving stimulating cytokines (eg IL-6).
The aforementioned studies indicate that suppression of the In contrast to the study by Thiele et al, 11 in 80% of patients 515-526. in our study, reticulin fibrosis in bone marrow was unchanged 5 Beelen DW, Graeven U, Elmaagacli AH et al. Prolonged adminis- or improved with IFN-␣ administration (Table 2a) marrow fibrosis in hairy cell leukemia was also seen only after 15 Thiele J, Kvasnicka HM, Zankovich R, Fischer R, Diehl V. Parameters of predictive value in chronic myeloid leukemia -the proglong-term exposure and response to IFN-␣ therapy (12 to 18 nostic impact of histopathological variables in a multivariate months), 38 while fibrosis was reported to be increased in studregression analysis. Leuk Lymphoma 1991; 4: 63-74.
ies following short-term IFN-␣ exposure (6 to 8 months). could be that the speed of increasing fibrosis and the time of
